Ozempic for prediabetes: what the evidence actually supports

What did @dralilianrosinha actually say?

Honestly? It's hard to tell. The transcript associated with this video is garbled to the point of being incoherent, with references to Facebook teams, UK population counts, and instructions not to eat anything. None of that maps onto the caption's actual topic: whether semaglutide (Ozempic) is effective for prediabetic patients.

The video caption does make a real claim worth examining. It states that semaglutide "has been proven for obesity treatment" and suggests it is being widely recommended for people who are prediabetic. That premise is medically relevant and worth unpacking, even if the delivered content couldn't be verified from the transcript provided.

Because we cannot quote the creator's spoken words with confidence, this fact-check will focus on what the caption asserts and what the clinical record actually shows about semaglutide in prediabetes contexts.

Does the science back this up?

On the core question, yes, there is meaningful evidence, but with important caveats. Semaglutide is not FDA-approved specifically for prediabetes, and framing it as broadly "indicated" for prediabetic patients overstates the current regulatory picture.

The SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) showed that weekly semaglutide 2.4 mg reduced the risk of major cardiovascular events in adults with overweight or obesity. A secondary finding was meaningful reduction in progression toward type 2 diabetes among participants with prediabetes at baseline. Separately, the STEP 1 trial (Wilding et al., 2021, NEJM) demonstrated that semaglutide produced significant weight loss in non-diabetic adults with obesity, and weight loss itself is among the most effective interventions for prediabetes reversal.

The SCALE Obesity and Prediabetes trial using liraglutide (a related GLP-1 agonist) showed 80 percent of participants converted from prediabetes to normoglycemia after three years, versus 59 percent on placebo (le Roux et al., 2017, The Lancet). That's a different drug, but it supports the biological plausibility of the class.

What did they get wrong (or right)?

The caption gets the general direction right: GLP-1 receptor agonists show real promise in prediabetic populations, and clinicians are increasingly discussing off-label use. That much is fair to say.

Where things get murky is the word "indicated." Indicated has a specific meaning in medicine. Semaglutide is FDA-approved for type 2 diabetes (Ozempic) and chronic weight management in adults with obesity or overweight plus a weight-related condition (Wegovy). Prediabetes alone does not currently meet the approved indication threshold for either formulation.

Calling it "muito indicado" for prediabetic patients risks suggesting there is a formal clinical approval or consensus guideline that does not yet exist. Off-label prescribing happens, and sometimes for good reasons, but patients deserve to know the difference. Claiming the drug "has been proven" for obesity treatment is accurate for Wegovy specifically. Extending that proof to a prediabetes indication without qualification is where the caption oversimplifies.

What should you actually know?

If you are prediabetic, the evidence base for GLP-1 medications is genuinely interesting, but it does not replace the conversation you need to have with a licensed clinician about your specific situation.

First, lifestyle intervention remains the first-line recommendation. The Diabetes Prevention Program (Knowler et al., 2002, NEJM) showed that intensive lifestyle changes reduced diabetes progression by 58 percent, outperforming metformin in that study. Any medication discussion should happen alongside, not instead of, that evidence.

Second, semaglutide is not a single drug. Ozempic and Wegovy contain the same molecule at different approved doses for different conditions. Compounded versions of semaglutide are not the same as FDA-approved brand-name products, and patients should understand that distinction clearly before making any decisions.

Third, the question of who benefits most from GLP-1 therapy in prediabetes is still being studied. Factors including BMI, baseline HbA1c, and cardiovascular risk profile all affect whether a prescriber might reasonably consider this option off-label. A TikTok caption cannot make that determination for you.